CN114450292A - 断裂型内含肽、使用其的重组多肽的制备方法 - Google Patents

断裂型内含肽、使用其的重组多肽的制备方法 Download PDF

Info

Publication number
CN114450292A
CN114450292A CN202080063341.7A CN202080063341A CN114450292A CN 114450292 A CN114450292 A CN 114450292A CN 202080063341 A CN202080063341 A CN 202080063341A CN 114450292 A CN114450292 A CN 114450292A
Authority
CN
China
Prior art keywords
flanking sequence
sequence
flanking
intein
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080063341.7A
Other languages
English (en)
Inventor
张敬
罗芳
龚承
王鑫
方丽娟
周鹏飞
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wuhan Youzhiyou Biopharmaceutical Co ltd
Original Assignee
Wuhan Youzhiyou Biopharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wuhan Youzhiyou Biopharmaceutical Co ltd filed Critical Wuhan Youzhiyou Biopharmaceutical Co ltd
Publication of CN114450292A publication Critical patent/CN114450292A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C07K5/06069—Ser-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Abstract

涉及了用于SspDnaE、SspDnaB、MxeGyrA、MjaTFIIB、PhoVMA、TvoVMA、Gp41‑1、Gp41‑8、IMPDH‑1或PhoRadA断裂型内含肽的侧翼序列对。所述侧翼序列对包括：侧翼序列a和侧翼序列b；所述侧翼序列a位于断裂型内含肽N端蛋白质剪接区域(In)的N端，且介于N端外显肽(En)和In之间；所述侧翼序列b位于断裂型内含肽C端蛋白质剪接区域(Ic)的C端，且介于Ic和C端外显肽(Ec)之间。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN202080063341.7A 2019-09-09 2020-09-09 断裂型内含肽、使用其的重组多肽的制备方法 Pending CN114450292A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910850928 2019-09-09
CN2019108509281 2019-09-09
PCT/CN2020/114271 WO2021047558A1 (zh) 2019-09-09 2020-09-09 断裂型内含肽、使用其的重组多肽的制备方法

Publications (1)

Publication Number Publication Date
CN114450292A true CN114450292A (zh) 2022-05-06

Family

ID=74865664

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080063341.7A Pending CN114450292A (zh) 2019-09-09 2020-09-09 断裂型内含肽、使用其的重组多肽的制备方法
CN202080063323.9A Pending CN114450406A (zh) 2019-09-09 2020-09-09 一种断裂型内含肽、使用其的重组多肽的制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202080063323.9A Pending CN114450406A (zh) 2019-09-09 2020-09-09 一种断裂型内含肽、使用其的重组多肽的制备方法

Country Status (3)

Country Link
US (2) US20220340677A1 (zh)
CN (2) CN114450292A (zh)
WO (2) WO2021047559A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115028741A (zh) * 2022-06-21 2022-09-09 苏州工业园区唯可达生物科技有限公司 一种肿瘤抗原抗体复合物及制备方法和应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023087255A1 (zh) * 2021-11-19 2023-05-25 武汉友芝友生物制药股份有限公司 双特异性抗体及其应用
WO2024082269A1 (zh) * 2022-10-21 2024-04-25 武汉友芝友生物制药股份有限公司 双特异性抗体在免疫细胞治疗方面的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110124841A1 (en) * 2007-12-13 2011-05-26 Monthony James F Polypeptides Modified by Protein Trans-Splicing Technology
CN104053779A (zh) * 2011-09-28 2014-09-17 时代生物技术股份公司 断裂内含肽及其用途
US20150344549A1 (en) * 2012-06-27 2015-12-03 The Trustees Of Princeton University Split inteins, conjugates and uses thereof
WO2017143839A1 (zh) * 2016-02-23 2017-08-31 上海交通大学 基于内含肽的药用重组蛋白的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7476500B1 (en) * 2001-03-19 2009-01-13 President And Fellows Of Harvard College In vivo selection system for enzyme activity
CN101899489A (zh) * 2009-05-27 2010-12-01 南京大学 利用内含肽反式剪接模式化生产融合蛋白质
EP3003357A1 (en) * 2013-05-31 2016-04-13 Novo Nordisk A/S Methods for producing peptides using engineered inteins
EP2883953A1 (en) * 2013-12-12 2015-06-17 Westfälische Wilhelms-Universität Münster An atypical naturally split intein engineered for highly efficient protein modification
WO2016069774A1 (en) * 2014-10-28 2016-05-06 Agrivida, Inc. Methods and compositions for stabilizing trans-splicing intein modified proteases
CA3051195A1 (en) * 2016-01-29 2017-08-03 The Trustees Of Princeton University Split inteins with exceptional splicing activity
CN106397598B (zh) * 2016-02-23 2020-07-14 上海交通大学 多价多特异性抗体及免疫杂合蛋白的表达和制备方法
CN106397599B (zh) * 2016-02-23 2020-08-07 上海交通大学 二价双特异性抗体杂交蛋白的表达和制备方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110124841A1 (en) * 2007-12-13 2011-05-26 Monthony James F Polypeptides Modified by Protein Trans-Splicing Technology
CN104053779A (zh) * 2011-09-28 2014-09-17 时代生物技术股份公司 断裂内含肽及其用途
US20150344549A1 (en) * 2012-06-27 2015-12-03 The Trustees Of Princeton University Split inteins, conjugates and uses thereof
WO2017143839A1 (zh) * 2016-02-23 2017-08-31 上海交通大学 基于内含肽的药用重组蛋白的合成方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MANOJ CHERIYAN等: "Traceless Splicing Enabled by Substrate-Induced Activation of the Nostoc punctiforme Npu DnaE Intein after Mutation of a Catalytic Cysteine to Serine", J. MOL. BIOL. *
魏新元;: "内含肽的研究及应用进展", 西北农林科技大学学报(自然科学版) *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115028741A (zh) * 2022-06-21 2022-09-09 苏州工业园区唯可达生物科技有限公司 一种肿瘤抗原抗体复合物及制备方法和应用

Also Published As

Publication number Publication date
WO2021047558A1 (zh) 2021-03-18
US20220340677A1 (en) 2022-10-27
US20220332757A1 (en) 2022-10-20
CN114450406A (zh) 2022-05-06
WO2021047559A1 (zh) 2021-03-18

Similar Documents

Publication Publication Date Title
CN114450292A (zh) 断裂型内含肽、使用其的重组多肽的制备方法
Wranik et al. LUZ-Y, a novel platform for the mammalian cell production of full-length IgG-bispecific antibodies
TW201831516A (zh) 抗gpc3抗體
US20200240998A1 (en) Quantitation and Identification of Dimers In Co-Formulations
US20230280354A1 (en) Methods for characterizing disulfide bonds
JP2023052110A (ja) タンパク質を同定及び定量化する方法及びシステム
US10604586B2 (en) Humanized monoclonal antibody and uses thereof
US20220265819A1 (en) Tau epitope and binding molecules
CN113677702A (zh) 针对利拉鲁肽的抗体及其用途
WO2023164145A1 (en) Size exclusion chromatography for characterizing host cell proteins
Deng et al. Detection and quantification of the human IgG4 half‐molecule, HL, from unpurified cell‐culture supernatants
KR20230026434A (ko) 미처리된 c-말단 리신을 정확하게 측정하기 위한 중질 펩티드 접근법
Dimasi et al. Guiding bispecific monovalent antibody formation through proteolysis of IgG1 single-chain
US11505614B2 (en) Antibodies binding to soluble BCMA
WO2015129651A1 (ja) 改変単量体ＩｇＭ
US20220064298A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CTLA-4
US20230002445A1 (en) Coupling isoelectric focusing-based fractionation with mass spectrometry analysis
JP2023542858A (ja) 水素交換質量分析を使用した、結合部位の同定のための方法
TW202337899A (zh) 透過proteominer改善序列變異分析
JP2023121725A (ja) 抗ＳＡＲＳ－ＣｏＶ－２抗体及びその製造方法
Jefferis et al. Structure and Function of Antibodies
US10793619B2 (en) Preparation and selection of cells for producing bispecific antibodies
WO2024083925A2 (en) Novel anti-napi2b antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof
JP2024507571A (ja) モノクローナル抗体の改善されたタンパク質配列決定のための電子移動解離及び質量分析方法
JP2021530989A (ja) ＰＤ−Ｌ１を標的とした改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination